LLY

748.08

-0.86%↓

JNJ

177.42

-0.37%↓

ABBV

217.75

-0.25%↓

UNH

347.95

-1.4%↓

AZN

78.06

-1.86%↓

LLY

748.08

-0.86%↓

JNJ

177.42

-0.37%↓

ABBV

217.75

-0.25%↓

UNH

347.95

-1.4%↓

AZN

78.06

-1.86%↓

LLY

748.08

-0.86%↓

JNJ

177.42

-0.37%↓

ABBV

217.75

-0.25%↓

UNH

347.95

-1.4%↓

AZN

78.06

-1.86%↓

LLY

748.08

-0.86%↓

JNJ

177.42

-0.37%↓

ABBV

217.75

-0.25%↓

UNH

347.95

-1.4%↓

AZN

78.06

-1.86%↓

LLY

748.08

-0.86%↓

JNJ

177.42

-0.37%↓

ABBV

217.75

-0.25%↓

UNH

347.95

-1.4%↓

AZN

78.06

-1.86%↓

Search

Ionis Pharmaceuticals Inc

Затворен

СекторЗдравеопазване

61.11 -3.22

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

60.61

Максимум

63.16

Ключови измерители

By Trading Economics

Приходи

270M

124M

Продажби

320M

452M

Марж на печалбата

27.331

Служители

1,069

EBITDA

294M

150M

Препоръки

By TipRanks

Препоръки

Купи

12-месечна прогноза

+8.53% upside

Пазарни показатели

By TradingEconomics

Пазарна капитализация

3.2B

9.7B

Предишно отваряне

64.33

Предишно затваряне

61.11

Настроения в новините

By Acuity

13%

87%

14 / 371 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Neutral Evidence

Ionis Pharmaceuticals Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

15.09.2025 г., 22:39 ч. UTC

Придобивния, сливания и поглъщания

CSL Agrees to Deal to Advance Coagulation Treatment, May Acquire Developer

15.09.2025 г., 16:43 ч. UTC

Значими двигатели на пазара

Strive Shares Sink on Board Disclosure; Bitcoin Treasury Strategy

15.09.2025 г., 16:42 ч. UTC

Значими двигатели на пазара

Helius Medical Tech Jumps on Funding to Launch Solana Treasury

15.09.2025 г., 16:35 ч. UTC

Значими двигатели на пазара

Chegg to Pay $7.5 Million to Settle FTC Claims Over Subscription Cancellation Process

15.09.2025 г., 23:46 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

15.09.2025 г., 23:46 ч. UTC

Пазарно говорене

Nikkei May Rise as Fed Rate Cut Hopes Support Stocks -- Market Talk

15.09.2025 г., 23:34 ч. UTC

Пазарно говорене

Gold Steady Ahead of FOMC Meeting, Major U.S. Economic Data -- Market Talk

15.09.2025 г., 22:48 ч. UTC

Пазарно говорене

FOMC May Opt to Play Catch Up With Rate Cuts -- Market Talk

15.09.2025 г., 22:12 ч. UTC

Придобивния, сливания и поглъщания

CSL Expects Commercial Launch in 2029

15.09.2025 г., 22:12 ч. UTC

Придобивния, сливания и поглъщания

CSL Says VarmX to Receive Further Commercial Milestones Afterwards

15.09.2025 г., 22:11 ч. UTC

Придобивния, сливания и поглъщания

CSL Says VarmX to Receive Payments of Up to $388 Million Up to Launch of VMX-C001

15.09.2025 г., 22:11 ч. UTC

Придобивния, сливания и поглъщания

CSL to Have Right to Exercise Option Based on Phase 3 Data

15.09.2025 г., 22:10 ч. UTC

Придобивния, сливания и поглъщания

CSL to Make Upfront Payment to VarmX of $117 Million for Exclusive Option to Acquire Company

15.09.2025 г., 21:16 ч. UTC

Придобивния, сливания и поглъщания

Chord Energy: Assets Have a Low Avg NYMEX WTI Breakeven and Are Immediately Competitive for Capital

15.09.2025 г., 21:16 ч. UTC

Придобивния, сливания и поглъщания

Chord Energy: Assets Have Significant Overlap With Existing Footprint, Setting the Stage for Long-Lateral Development

15.09.2025 г., 21:15 ч. UTC

Придобивния, сливания и поглъщания

Chord Energy to Buy 48,000 Net Acres in the Williston Core

15.09.2025 г., 21:14 ч. UTC

Придобивния, сливания и поглъщания

Chord Energy to Buy Assets in Williston Basin From Exxon's XTO Energy and Affiliates for $550M

15.09.2025 г., 20:50 ч. UTC

Пазарно говорене

Auto & Transport Roundup: Market Talk

15.09.2025 г., 20:50 ч. UTC

Пазарно говорене

Financial Services Roundup: Market Talk

15.09.2025 г., 20:50 ч. UTC

Пазарно говорене

Basic Materials Roundup: Market Talk

15.09.2025 г., 19:29 ч. UTC

Пазарно говорене

U.S. Natural Gas Gains on Warmer Weather Outlook -- Market Talk

15.09.2025 г., 19:14 ч. UTC

Пазарно говорене

Attacks on Russia Lifts Oil Price Despite Shaky Fundamentals -- Market Talk

15.09.2025 г., 18:16 ч. UTC

Пазарно говорене

Gold Powers to New High -- Market Talk

15.09.2025 г., 18:05 ч. UTC

Пазарно говорене

Easing Autonomous Vehicle Regulations Will Begin Tesla's Next Chapter -- Market Talk

15.09.2025 г., 17:50 ч. UTC

Придобивния, сливания и поглъщания

U.S. Reaches Outline of Deal With China Over TikTok -- 2nd Update

15.09.2025 г., 17:10 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

15.09.2025 г., 17:10 ч. UTC

Пазарно говорене

S&P Expects Fed, BOC to Cut Rates -- Market Talk

15.09.2025 г., 16:52 ч. UTC

Пазарно говорене

Copper Climbs as Traders Brace for U.S. Rate Cut -- Market Talk

15.09.2025 г., 16:20 ч. UTC

Пазарно говорене

Financial Services Roundup: Market Talk

15.09.2025 г., 16:20 ч. UTC

Пазарно говорене
Печалби

Auto & Transport Roundup: Market Talk

Сравнение с други в отрасъла

Ценова промяна

Ionis Pharmaceuticals Inc Прогноза

Ценова цел

By TipRanks

8.53% нагоре

12-месечна прогноза

Среден 68.55 USD  8.53%

Висок 96 USD

Нисък 43 USD

Според 21 анализатори от Wall Street, предложили 12-месечна ценова цел за Ionis Pharmaceuticals Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Купи

21 ratings

16

Купи

4

Задържане

1

Продай

Техническа оценка

By Trading Central

29.78 / 33.645Подкрепа & съпротива

Краткосрочен план

Neutral Evidence

Средносрочен план

Very Strong Bullish Evidence

Дългосрочен план

Bearish Evidence

Настроение

By Acuity

14 / 371 Класиране в Здравеопазване

Настроения в новините

Много силни бичи доказателства

Волатилност

Под средното

Обем новини (RCV)

Под средното

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

$

Относно Ionis Pharmaceuticals Inc

Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy. It also develops medicines for various indications that are in phase 3 study, including Eplontersen as a monthly self-administered subcutaneous injection to treat all types of ATTR; Olezarsen for patients with FCS and severe hypertriglyceridemia (SHTG); Donidalorsen for patients with hereditary angioedema; ION363 for patients with amyotrophic lateral sclerosis; Tofersen to inhibit the production of superoxide dismutase 1; Pelacarsen for patients with established cardiovascular disease and elevated lipoprotein(a); and Bepirovirsen to inhibit the production of viral proteins associated with hepatitis B virus. In addition, the company develops IONIS-FB-LRx to inhibit the production of complement factor B and the alternative complement pathway; and ION224 to reduce the production of diacylglycerol acyltransferase 2. It has a strategic collaboration with Biogen for the treatment of neurological disorders; and collaboration and license agreement with Metagenomi, Inc, AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis, Roche, Swedish Orphan Biovitrum AB, and PTC Therapeutics. The company was incorporated in 1989 and is based in Carlsbad, California.
help-icon Live chat